We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+26.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$494M
AUM Growth
+$67.8M
Cap. Flow
-$71M
Cap. Flow %
-14.37%
Top 10 Hldgs %
52.79%
Holding
80
New
31
Increased
8
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$15.7M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$12.1M
4
FOLD
Amicus Therapeutics
FOLD
+$11.4M
5
GYRE icon
Gyre Therapeutics
GYRE
+$11.2M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$15.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$9.37M

Sector Composition

Rank Sector Weight
1 Healthcare 63.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
51
AnaptysBio
ANAB
$1.72B
$937K 0.19%
+9,000
New +$1.01M
MOTS
52
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$448K 0.09%
+333
New +$469K
IMGN
53
DELISTED
Immunogen Inc
IMGN
$225K 0.05%
+7,500
New +$74.1K
BMY icon
54
CALL
Bristol-Myers Squibb
BMY
$124B
– –
-150,000
Closed -$9.19M
CRSP icon
55
CRISPR Therapeutics
CRSP
$4.71B
– –
-150,000
Closed -$3.52M
EDIT icon
56
Editas Medicine
EDIT
$457M
– –
-65,000
Closed -$2M
ESPR
57
DELISTED
Esperion Therapeutics
ESPR
– –
-230,000
Closed -$15.1M
FXB icon
58
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
– –
-9,100
Closed -$1.19M
INCY icon
59
Incyte
INCY
$23.4B
– –
-50,000
Closed -$4.51M
IRTC icon
60
iRhythm Holdings
IRTC
$3.64B
– –
-65,000
Closed -$3.64M
NTLA icon
61
Intellia Therapeutics
NTLA
$1.59B
– –
-175,000
Closed -$3.36M
RIGL icon
62
Rigel Pharmaceuticals
RIGL
$750M
– –
-82,500
Closed -$3.2M
RYTM icon
63
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-25,000
Closed -$727K
SAGE
64
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-43,700
Closed -$7.2M
GBT
65
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-325,000
Closed -$12.8M
XLRN
66
DELISTED
Acceleron Pharma
XLRN
– –
-200,000
Closed -$8.49M
ALXN
67
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-115,000
Closed -$13.8M
GNMK
68
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-500,000
Closed -$2.08M
IMMU
69
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-1,300,000
Closed -$21M
AIMT
70
DELISTED
Aimmune Therapeutics
AIMT
– –
-158,200
Closed -$5.98M
PTLA
71
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-225,000
Closed -$11M
AGN
72
CALL
DELISTED
Allergan plc
AGN
– –
-75,000
Closed -$12.3M
DERM
73
DELISTED
Dermira, Inc.
DERM
– –
-100,000
Closed -$2.78M
ARRY
74
DELISTED
Array Biopharma Inc
ARRY
– –
-500,000
Closed -$6.4M
HZNP
75
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-400,000
Closed -$5.84M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Ghost Tree Capital held 80 positions worth $494M, up 16% from $426M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ghost Tree Capital withdrew a net $71M in Q1 2018, closing 27 positions and reducing 10 holdings. Its most notable exit was Esperion Therapeutics, an estimated $15.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 52% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $17.4M.

  • Ghost Tree Capital's largest Q1 2018 buy was Sarepta Therapeutics: 235,000 shares worth $17.4M.
  • Ghost Tree Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $10.9M increase.
  • Ghost Tree Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $9.37M.
  • Ghost Tree Capital fully exited Esperion Therapeutics in Q1 2018, selling an estimated $15.1M.
  • Ghost Tree Capital's ten largest holdings make up 53% of its $494M portfolio in Q1 2018.
  • Ghost Tree Capital opened 31 new positions and closed 27 in Q1 2018.
  • Ghost Tree Capital's portfolio value rose 16% quarter-over-quarter to $494M.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.